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Background: Forced expiratory volume in 1 second (FEV
1
) grades severity of COPD and 
predicts survival. We hypothesize that the inspiratory capacity/total lung capacity (IC/TLC) 
ratio, a sensitive measure of static lung hyperinflation, may have a significant association with 
survival in an emphysematous phenotype of COPD.
Objectives: To access the association between IC/TLC and survival in an emphysematous 
phenotype of COPD. 
Methods: We performed a retrospective analysis of a large pulmonary function (PF) database 
with 39,050 entries, from April 1978 to October 2009. Emphysematous COPD was defined as 
reduced FEV
1
/forced vital capacity (FVC), increased TLC, and reduced diffusing capacity of 
the lungs for carbon monoxide (DLCO; beyond 95% confidence intervals [CIs]). We evalu-
ated the association between survival in emphysematous COPD patients and the IC/TLC ratio 
evaluated both as dichotomous (25% vs 25%) and continuous predictors. Five hundred and 
ninety-six patients had reported death dates.
Results: Univariate analysis revealed that IC/TLC 25% was a significant predictor of death 
(hazard ratio [HR]: 2.39, P0.0001). Median survivals were respectively 4.3 (95% CI: 3.8–4.9) 
and 11.9 years (95% CI: 10.3–13.2). Multivariable analysis revealed age (HR: 1.19, 95% CI: 
1.14–1.24), female sex (HR: 0.69, 95% CI: 0.60–0.83), and IC/TLC 25% (HR: 1.69, 95% 
CI: 1.34–2.13) were related to the risk of death. Univariate analysis showed that continuous 
IC/TLC was associated with death, with an HR of 1.66 (95% CI: 1.52–1.81) for a 10% decrease 
in IC/TLC.
Conclusion: Adjusting for age and sex, IC/TLC 25% is related to increased risk of death, 
and IC/TLC as a continuum, is a significant predictor of mortality in emphysematous COPD 
patients. 
Keywords: emphysema, pulmonary function testing, mortality
Introduction
COPD represents an important public health challenge that is both treatable and 
preventable.1 Currently, COPD is the fourth leading cause of death worldwide and 
is expected to be the third leading cause of death by 2020.2 Despite efforts from the 
medical community, the Centers for Disease Control (CDC) reports that smoking rates 
in the US have only slightly declined since 1997 from 24.7% to 20.8%.3 With COPD 
prevalence increasing, accurate assessments of COPD comorbidities and mortality 
are needed.4–25 COPD results from the interplay between genetic susceptibility and 
exposure to environmental stimuli.26
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In 1977, Fletcher and Peto described the natural history 
of COPD, including its relationship with smoking and 
decline in forced expiratory volume in 1 second (FEV
1
).27 
Since that time, COPD has been characterized as a poorly 
reversible airflow limitation, most often defined by FEV
1
.8 
Historically, the reduction in FEV
1
 has been used to define 
the severity of COPD and frequently cited as an important 
predictor of mortality.24 Additionally, FEV
1
 is frequently 
targeted as a clinical endpoint in COPD clinical trials.28–34 
Other clinical measurements such as inspiratory capacity 
(IC), 6-minute walk test (6MWT), the BODE index (body 
mass index, airflow obstruction, dyspnea, and exercise), and 
dyspnea questionnaires may have stronger associations with 
mortality than FEV
1
.7,12–16,19,24,35–39
Several publications have focused on the use of the IC/
total lung capacity (TLC) ratio, a measure of static lung 
hyperinflation, which has been shown to be strongly associ-
ated with exercise-associated dynamic hyperinflation as well 
as exercise tolerance.4,8,38,40 Additionally, studies evaluat-
ing the use of resting IC have also demonstrated a strong 
association between IC and functional exercise limitation 
in COPD patients.41,42 In 2004, Casanova et al evaluated 
the role of the IC/TLC ratio, in conjunction with the BODE 
index and FEV
1
.7 Their cohort consisted of 689 patients 
(95% male) with 183 deaths (178 males and five females) 
with a median follow-up less than 3 years; their results sug-
gested that when compared to FEV
1
 and the BODE index, an 
IC/TLC ratio of 25% offered the best combined sensitivity 
and specificity for predicting all-cause mortality in COPD 
patients.7 We hypothesize that the IC/TLC ratio is associ-
ated with risk of death, when used to evaluate a large cohort 
over an extended period of follow-up and could be a useful 
clinical tool in assessing patients with an emphysematous 
phenotype of COPD. 
Methods 
We performed a retrospective analysis of a large pulmonary 
function (PF) database, consisting of 39,050 entries, from our 
institution, which encompasses a broad patient population of 
inpatients and outpatients from April 1978 to October 2009. 
Cedars-Sinai Medical Center Institutional Review Board 
approval (Pro-00012916) was obtained for the study. We 
evaluated the IC/TLC ratio and its association with survival. 
All available studies were evaluated, which consisted of 
39,050 entries. We defined COPD patients with an emphyse-
matous phenotype as those with a reduced FEV
1
/FVC ratio, 
increased TLC, and reduced diffusing capacity of the lungs 
for carbon monoxide (DLCO; all beyond 95% confidence 
intervals) using established normal values.42–44 If the same 
patient had multiple PF studies, only the first recorded PF was 
included in the study analysis. Lastly, patients were excluded 
if they were under the age of 18 years. Using the Social Secu-
rity National Death Index (SSNDI), we established absolute 
dates of death. If the subject did not have a reported date of 
death in the SSNDI, they were assumed to be alive 8 weeks 
prior to the date that the SSNDI was queried. Univariate 
analysis was completed to evaluate the relationship between 
IC/TLC ratio and survival. Additionally, disease severity was 
graded using the FEV
1
 as defined by the Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) criteria.46 
Body mass index (BMI) was treated as ordered categories 
(BMI:  20 low, 20–25 normal, 25 overweight/obese). 
As done previously in the NETT trial, DLCO was treated as a 
binary variable, with a cut-off of 22%.47 Finally, multivari-
able analysis assessing the associations of age, sex, FEV
1
, 
DLCO, IC, and BMI in conjunction with the IC/TLC ratio 
was performed. All studies were performed on equipment 
manufactured by the SensorMedics Corporation. IC measure-
ments were made during the enhanced spirometry section 
with deep inspiration occurring after a period of stable tidal 
breathing; all tests were performed according to the Ameri-
can Thoracic Society (ATS) criteria. Single-breath DLCO 
measurements were made according to ATS criteria with a 
10-second breath-hold; correction for hemoglobin was not 
performed. TLC was measured using plethysmography as per 
ATS criteria. Forced expiratory spirometry was obtained 
pre- and post-spirometry; plethysmography was obtained 
post-bronchodilator.
Numerical variables were summarized by mean and stan-
dard deviation or median and interquartile range (IQR), as 
appropriate, depending on the normality of the distribution. 
Group differences on numerical variables were assessed by 
Student’s t-tests (normality was satisfied) or the Wilcoxon 
rank-sum test (normality was violated). Categorical vari-
ables were summarized by frequency and percentage and 
compared across groups by the chi-square test or Fisher’s 
exact test, as appropriate. Survival was estimated by the 
Kaplan–Meier method. Group differences in survival were 
assessed by the log-rank test. Survival differences across 
ordinal explanatory variables were assessed by trend tests. 
Factors associated with the risk of death were assessed by 
multivariable Cox proportional hazards models. The propor-
tional hazards assumption was assessed by the supremum test 
and by analysis of Schoenfeld residuals. Hazard ratios (HRs) 
and their associated 95% CIs were reported where possible. 
Two-sided P-values were reported for all comparisons. 
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Statistical calculations were made using SAS software 
(v9.1.3; SAS Institute Inc., Cary, NC, USA).
Results
Our database consisted of 39,050 PF tests; 14,322 were 
excluded because they had no DLCO recorded. The remain-
ing 24,728 PFs that were excluded, either did not meet cri-
teria for obstruction or were repeat PF tests. Nine-hundred 
and eighty-four patient PFs meeting criteria were ana-
lyzed (Figure 1). The study cohort consisted of 436 females 
and 548 males. Five hundred and ninety-six subjects had 
reported dates of death. 
Baseline characteristics are reported in Table 1. As dis-
played in Table 1, there were notable differences between the 
‘dead’ and ‘alive’ groups. ‘Alive’ patients were younger, had 
a higher BMI, a higher FEV
1
/FVC ratio, and higher predicted 
FEV
1
 with a larger percentage being defined as having mild 
COPD. In regards to lung volumes, ‘alive’ patients had a 
slightly lower TLC, higher DLCO, higher IC, and had better 
IC/TLC ratios than patients in the ‘dead’ group. 
The potential predictors of all-cause mortality are shown 
in Tables 2 and 3.
Univariate analysis revealed that IC/TLC, % DLCO, sex, 
age, BMI, IC, and FEV
1
 were all significantly associated 
with survival (Table 2; Figures 2, 3, and 4). Using an IC/
TLC 25% compared to IC/TLC 25%, there was a sig-
nificant decrease in survival (HR: 2.39, 95% CI: 2.03–2.82, 
P0.0001). The median survival was 4.3 years for IC/
TLC 25% (95% CI: 3.8–4.9 years) versus 11.9 years for 
IC/TLC 25% (95% CI: 10.3–13.2 years). Five-year survival 
for IC/TLC 25% versus IC/TLC 25% was 43.9% (95% 
CI: 38.7%–49.0%) versus 73.4% (95% CI: 69.6%–76.9%), 
respectively. Additionally, a DLCO 22% versus a 
DLCO 22% was associated with an increased risk of death 
(HR: 2.08, 95% CI: 1.68–2.57, P0.0001). The median sur-
vival for a DLCO 22% was 3.77 years (95% CI: 2.94–4.60 
years). Females had reduced risk of death (HR: 0.78, 95% 
CI: 0.66–0.92, P=0.003). Median survival for females was 
8.7 years (95% CI: 7.7–10.1 years) versus 7.0 years for males 
(95% CI: 5.7–8.2 years). A 5-year increase in age revealed a 
23% increased risk of death (HR: 1.23, 95% CI: 1.18–1.28, 
P0.0001). Compared to a normal BMI (20 to 25, the 
reference level), patients with a BMI 20 were at greater 
risk of death (HR: 1.22, 95% CI: 0.99–1.51, P=0.068). 
However, a BMI 25 appeared to be protective (HR: 0.81, 
95% CI: 0.67–0.97, P=0.022). An IC 80% was associated 
with a reduced risk of death (HR: 0.48, 95% CI: 0.41–0.57, 
P0.0001). Lastly, FEV
1
 was evaluated using moderate 
COPD disease, as defined by GOLD criteria, as the refer-
ence group: patients with mild COPD were less likely to die 
(HR: 0.48, 95% CI: 0.35–0.65, P0.001); however, both 
severe (HR: 1.38, 95% CI: 1.11–1.70, P=0.003) and very 
severe COPD (HR: 1.81, 95% CI: 1.46–2.23, P0.0001) 
patients were at increased risk of death.
In addition, a multivariable analysis was preformed to 
assess the associations of age, sex, FEV
1
, % DLCO, IC, 
and BMI in conjunction with the IC/TLC ratio. Analysis 
revealed that age (5-year increase in age), sex, IC/TLC 25%, 
FEV
1
, BMI 20, and DLCO 22% remained statistically 
significant factors associated with the risk of death (Table 3). 
Patients with a DLCO 22% had an increased risk of death 
when compared to patients with a DLCO 22% (HR: 1.28, 
95% CI: 1.01–1.61, P=0.043) (Figure 5). Compared to a 
normal BMI (20 to 25, the reference level), patients with 
??????
????????????
?????????
??????????????
???????????
?????????????????????????????
???????????????? ?????????????? ???????????????????????? ?????????????????? ?????????????????? ???????????????
?????????????????? ?????????????? ???????????????????????? ?????????????????? ?????????????????? ??????????????
Figure 1 Patient flow chart.
Abbreviations: CI, confidence interval; DLCO, diffusing capacity of the lungs for carbon monoxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; 
IC, inspiratory capacity; PFTS, pulmonary function test; pts, patients; SSN, Social Security number; TLC, total lung capacity.
International Journal of COPD 2015:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1308
French et al
a BMI 20 were at greater risk of death (HR: 1.22, 95% 
CI: 0.97–1.53, P=0.089). In contrast, a BMI 25 appeared 
to be protective (HR: 0.81, 95% CI: 0.67–0.97, P=0.022) 
(Figure 6). Lastly, FEV
1
 was evaluated using moderate COPD 
disease, as defined by GOLD criteria, as the reference group. 
Patients with mild COPD were less likely to die (HR: 0.66, 
95% CI: 0.48–0.90, P=0.009). Additionally, neither severe 
(HR: 1.01, 95% CI: 0.80–1.27, P=0.95) nor very severe COPD 
(HR: 1.06, 95% CI: 0.79–1.41, P=0.71) patients were at 
increased risk of death, compared to the moderate group in 
the multivariate analysis. In summary, increasing age, IC/
TLC 25%, DLCO 22%, and a BMI 20 were associated 
with increased risk of death. Female sex and a higher BMI 
were protective.
Lastly, we completed a univariate analysis of the IC/
TLC ratio as a continuous predictor of the risk of death. 
Over the entire range of IC/TLC (8%–63%), a 10% decrease 
in IC/TLC was associated with a 66% increase in the 
risk of death (HR: 1.66, 95% CI: 1.52–1.81, P0.0001). 
For clinical applicability, we categorized the ratio into 
Table 1 Baseline characteristics and univariate analysis 
Variable All patients
(N=984)
Alive
(N=388)
Dead
(N=596)
P-value
Female, n (%) 436 (44.3) 191 (49.2) 245 (41.1) 0.013
age, mean years ± sD 62.7±12.1 58.2±13.3 65.6±10.3 0.0001
BMI, mean ± sD 24.2±4.6 25.0±4.5 23.7±4.6 0.0001
FEV1/FVC%, mean ± sD 46.8±13.4 51.8±13.7 43.5±12.2 0.0001
FEV1 predicted %, mean ± sD 50.2±25.49 57.9±26.79 45.1±23.29 0.0001
stage (gOlD) 0.0001
Mild, 80% of predicted, n (%) 162 (16.5) 106 (27.3) 56 (9.4)
Moderate, 50%–79% of predicted, n (%) 265 (26.9) 107 (27.6) 158 (26.5)
severe, 30%–49% of predicted, n (%) 283 (28.8) 99 (25.5) 184 (30.9)
Very severe, 30% of predicted, n (%) 274 (27.8) 76 (19.6) 198 (33.2)
% TlC, mean ± sD 135.15±11.12 133.7±10.17 136.1±11.56 0.001
% DlCO, mean ± sD 43.2±17.74 49.9±17.59 38.8±16.43 0.0001
DlCO 22%, n (%) 126 (12.8) 21 (5.4) 105 (17.6) 0.0001
% IC, mean ± sD 92.0±27.74 98.8±26.79 87.7±27.53 0.0001
IC 80%, n (%) 632 (64.2) 295 (76.0) 337 (56.5) 0.0001
BMI 0.0001
low, 20, n (%) 176 (17.9) 52 (13.4) 124 (20.8)
normal, 20 to 25, n (%) 407 (41.4) 144 (37.1) 263 (44.1)
high 25, n (%) 401 (40.7) 192 (49.5) 209 (35.1)
IC/TlC, mean % ± sD 28.7±9.8 32.0±10.2 26.6±8.9 0.0001
IC/TlC 25%, n (%) 395 (40.1) 99 (25.5) 296 (49.7) 0.0001
Notes: Baseline characteristics of survivors and nonsurvivors. Subjects who died were more likely to be male, had greater airflow obstruction, an IC/TLC 25%, lower 
BMI, and were older.
Abbreviations: BMI, body mass index; DLCO, diffusing capacity of the lungs for carbon monoxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; 
GOLD, Global Initiative for Chronic Obstructive Lung Disease; IC, inspiratory capacity; SD, standard deviation; TLC, total lung capacity.
Table 2 Univariate analysis
Variable HR 95% CI P-value
age (5-year increase) 1.23 1.18–1.28 0.0001
Female 0.78 0.66–0.92 0.003
IC/TlC 25% 2.39 2.03–2.82 0.0001
FEV1 mild vs moderate 0.48 0.35–0.65 0.0001
FEV1 severe vs moderate 1.38 1.11–1.70 0.003
FEV1 very severe vs moderate 1.81 1.46–2.23 0.0001
BMI 20 vs BMI 20 to 25 1.22 0.99–1.51 0.068
BMI 25 vs BMI 20 to 25 0.81 0.67–0.97 0.022
DlCO 22% 2.08 1.68–2.57 0.0001
IC 80% 0.48 0.41–0.57 0.0001
Abbreviations: BMI, body mass index; CI, confidence interval; DlCO, diffusing 
capacity of the lungs for carbon monoxide; FEV1, forced expiratory volume in 
1 second; HR, hazard ratio; IC, inspiratory capacity; TLC, total lung capacity.
Table 3 Multivariable analysis
Variable HR 95% CI P-value
age (5-year increase) 1.19 1.14–1.24 0.0001
Female 0.69 0.58–0.83 0.0001
IC/TlC 25% 1.69 1.34–2.13 0.0001
FEV1 mild vs moderate 0.66 0.48–0.90 0.009
FEV1 severe vs moderate 1.01 0.80–1.27 0.95
FEV1 very severe vs moderate 1.06 0.79–1.41 0.71
BMI 20 vs BMI 20 to 25 1.22 0.97–1.53 0.089
BMI 25 vs BMI 20 to 25 0.81 0.67–0.97 0.022
DlCO 22% 1.28 1.01–1.61 0.043
Abbreviations: BMI, body mass index; CI, confidence interval; DlCO, diffusing 
capacity of the lungs for carbon monoxide; FEV1, forced expiratory volume in 1 
second; HR, hazard ratio; IC, inspiratory capacity; TLC, total lung capacity.
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four levels: IC/TLC 45% (the reference level), 35% 
to 45%, 25% to 35%, and 25% (Table 4; Figure 7). 
Compared to patients with IC/TLC 45%, patients with 
IC/TLC 35% to 45% were at 76% increased risk of death 
(HR: 1.76, 95% CI: 1.07–2.89); patients with IC/TLC 25% 
to 35% were at 182% increased risk of death (HR: 2.82, 
95% CI: 1.76–4.53); and patients with IC/TLC 25% were 
at 423% increased risk of death (HR: 5.23, 95% CI: 3.28–
8.35). Median survivals (95% CI) were 4.3 (3.8–4.9) years 
for patients with IC/TLC 25%, 8.9 (7.7–10.5) years for 
patients with IC/TLC 25% to 35%, and 14.1 (11.9–18.7) 
years for patients with IC/TLC 35% to 45%. Median 
survival was not yet reached in patients with IC/TLC 45% 
(30-year survival estimate 52.3%).
Discussion
Using an IC/TLC ratio of 25%, a representation of static lung 
hyperinflation, we were able to demonstrate that the IC/TLC 
ratio correlated with risk of death in patients with an emphy-
sematous phenotype of COPD. Patients with an IC/TLC ratio 
25% had a median survival of 4.3 years versus 11.9 years for 
those patients with an IC/TLC 25%. The use of the IC/TLC 
ratio, as a single predictor variable, in patients with COPD, 
will allow clinicians to better evaluate and risk-stratify patients 
with an emphysematous phenotype of COPD. 
In the 35 years since Fletcher and Peto described the 
natural history of COPD, our understanding about the dis-
ease process has been an ongoing development.27 Although 
initial studies supported FEV
1
 as the best predictor of COPD 
mortality,47 more recent literature has revealed that a variety 
of factors are more accurate predictors of mortality than 
FEV
1
.7,12–16,19,24,34–39 Interest has been shown in the role of 
the vitamin D pathway in COPD, with vitamin D deficiency 
correlating with the risk of COPD.26
In addition to IC/TLC and FEV
1
, we also examined the 
relationship of IC, age, BMI, DLCO, and sex (Tables 1 and 3) 
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Figure 2 Survival by predicted FEV1 level as defined by GOLD criteria.
Abbreviations: FEV1, forced expiratory volume in 1 second; GOLD, Global 
Initiative for Chronic Obstructive Lung Disease; PFT, pulmonary function test.
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Figure 3 Patient survival by IC/TlC.
Abbreviations: IC, inspiratory capacity; TLC, total lung capacity; PFT, pulmonary 
function test.
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Figure 4 Patient survival by sex.
Abbreviation: PFT, pulmonary function test.
? ?? ?? ???????????????? ?? ?? ??
????
????
????
????
????
???
????
?????
????
????
????
????
??
?
??????? ??????????????????
Figure 5 Patient survival by DlCO.
Abbreviations: DLCO, diffusing capacity of the lungs for carbon monoxide; PFT, 
pulmonary function test.
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and their associations with the risk of death. Specifically, 
our multivariable analysis demonstrated that IC alone was 
not a reliable predictor of mortality, contrary to what has 
been previously reported in a milder COPD population.24 
We were able to demonstrate that age and BMI were associ-
ated with risk of death but did not demonstrate as clear an 
association as the IC/TLC. In regards to sex, Kaplan–Meier 
analysis revealed that females had a survival advantage 
when compared directly to males with COPD. Ringbaek 
et al previously reported that when compared to standardized 
mortality rates expected in the general population, it appeared 
that females with COPD actually have more years of life lost 
than their male counterparts.21 Furthermore, when examin-
ing the DLCO, we found a significant association with risk 
of death. However, our cohort had only 126 patients with a 
DLCO 22%.
Our study had a number of strengths. To our knowledge, 
it is the first study to evaluate mortality over 34 years of 
reported data in an emphysematous phenotype of COPD. 
Additionally, our cohort consisted of 44.3% (436) females, 
and to date, is one of the largest cohorts of females used 
to evaluate COPD mortality. We used an easily identifi-
able IC/TLC cut-off of 25%, which has previously been 
validated.7
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Figure 6 survival by BMI level.
Abbreviations: BMI, body mass index; PFT, pulmonary function test.
Table 4 IC/TlC ratio in levels
Variable HR 95% CI P-value
IC/TlC levels
35% to 45% vs 45% 1.76 1.07–2.89 0.025
25% to 35% vs 45% 2.82 1.76–4.53 0.0001
25% vs 45% 5.23 3.28–8.35 0.0001
Abbreviations: CI, confidence interval; HR, hazard ratio; IC, inspiratory capacity; 
TlC, total lung capacity.
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Figure 7 Patient survived by IC/TlC level.
Abbreviations: IC, inspiratory capacity; TLC, total lung capacity; PFT, pulmonary 
function test.
The study does have limitations. It is a PF test-based 
study, assumptions about the patients’ clinical phenotype 
were made on the basis of PF data, and no smoking history 
or radiological data were available. We did not evaluate or 
compare the BODE index or 6MWT. On the other hand, we 
did evaluate other well-defined variables including age, BMI, 
and FEV
1
 in the analysis. We did not have PaO
2
 values, there-
fore could not evaluate/correlate the degree of hypoxemia 
and its role in survival. The study inclusion criteria required a 
DLCO for the patient to be included in the analysis. In doing 
so, we eliminated patients who may have obstructive disease 
secondary to asthma, but undoubtedly removed many patients 
with COPD. We did not evaluate specific cause of death as 
previous studies have done, which prevented us from exclud-
ing patients that died from nonrespiratory events.
Our study demonstrates that the IC/TLC ratio 25% is 
strongly related to risk of death in an emphysematous pheno-
type of COPD patients. When compared to FEV
1
 and other 
previously accepted variables, IC/TLC was a better predic-
tor of survival in both univariate and multivariate analysis. 
Specifically, we found FEV
1
 to be weakly associated with 
survival. When using patients with moderate severity as 
the reference group, those patients with mild disease were 
noted to have improved survival. Patients with severe and 
very severe disease did not have a statistically significant 
difference in mortality when compared to those individuals 
with moderately severe disease. 
We believe that the reduced IC/TLC ratio, reflective of 
static lung hyperinflation, plays an important role in patients 
with an emphysematous phenotype of COPD. As hyperinflation 
progresses, patients experience increasing dyspnea and reduced 
exercise capacity. Dynamic lung hyperinflation is associated 
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with increasing end-expiratory lung volumes, which is 
associated with airflow limitation and loss of elastic recoil. In 
COPD, emphysematous changes in the lung are secondary to 
destruction of the elastic tissue in the lung parenchyma. As 
the lung parenchyma loses it elasticity, lung recoil is reduced, 
resulting in a compensatory increase in functional reserve 
capacity (FRC); as the FRC increases, the IC is reduced.49 
Therefore, in patients with COPD, the relationship between 
IC and TLC gradually declines as static lung hyperinflation 
increases. We found that the IC/TLC ratio strongly correlates 
with risk of death. In addition to risk of death, static lung hyper-
inflation has been reported to correlate with exercise capacity 
and cardiac performance in patients with COPD, thus adding 
to the clinical use of the IC/TLC ratio.
Previous studies of COPD patients often refer to the FEV
1
 
and its rate of decline to define treatment success or failure. 
Current treatment guidelines are based on the GOLD-defined 
FEV
1
, an endpoint that we found to have little correlation 
with survival. We believe that the IC/TLC ratio may be a 
more relevant variable for such analysis, possible arguing 
for further studies. 
In conclusion, a significant number of COPD patients 
have PF tests that include measurement of lung volumes. 
The IC/TLC ratio, like the BODE index, has demonstrated 
a correlation with COPD survival, is easy to obtain, and 
should be considered in the assessment of patients with an 
emphysematous phenotype of COPD.
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